Navigation Links
First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment
Date:1/20/2010

SAN DIEGO, Jan. 20 /PRNewswire/ -- First Coast Oncology in Jacksonville, Florida has significantly enhanced its ability to treat breast cancer with the addition of a Naviscan PEM (Positron Emission Mammography) scanner.  The facility will be among the first in the nation to use both a PEM scanner and the AccuBoost image guided breast irradiation procedure to optimize their therapy treatment.

AccuBoost is a technique for whole breast irradiation that is designed to target and deliver a boost dose accurately and reliably to the lumpectomy cavity margin.  With PEM's three-dimensional metabolic perspective, physicians will be able to better visualize the region of interest prior to deploying the AccuBoost system, which lowers dose to healthy tissue as radiation is focused on the intended target sparing exposure to the heart, lungs and the uninvolved breast.

First Coast Oncology has three locations and focuses on providing the latest cancer treatment options available. "For more than 10 years, First Coast Oncology has provided the highest level of care to the women in Northeast Florida and Southeast Georgia who have been diagnosed with breast cancer," said Scot Ackerman, M.D., Medical Director of First Coast Oncology. "The acquisition of the Naviscan PEM scanner demonstrates First Coast Oncology's commitment to securing the latest technology to detect and treat breast cancer as well as being able to assess response to therapy. I expect that PEM will prove indispensable in the effective management of breast cancer for both our patients and referring physicians."

The Naviscan PEM scanner uses PET (Positron Emission Tomography) technology to produce high-resolution tomographic images at 2 millimeter resolution, allowing physicians to visualize breast tumors about the size of a grain of rice. The scanner is the size of a mammography unit and consists of two high-resolution detector heads which are placed in close proximity to the breast. Compared to the higher-force compression necessary for mammography, the Naviscan PEM scanner uses gentle breast immobilization.

About Naviscan, Inc.

Naviscan, Inc., founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging, guide radiological and surgical procedures and advance new clinical therapies.   The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. as well as utilized in clinical research studies, funded in part by the National Institutes of Health.  The Company is headquartered in San Diego, California and is the first company to obtain FDA clearance of a high-resolution PET scanner designed to image small body parts.   For more information, call 1.858.587.3641 or visit www.naviscan.com

About First Coast Oncology

First Coast Oncology's staff consists of board-certified radiation oncologists and medical physicists, certified medical dosimetrists, a nuclear medicine technologist, oncology certified nurses, oncology social workers, and radiation therapists.

First Coast Oncology offers convenient care at their state-of-the-art facilities throughout Northeast Florida. Their locations at Mandarin, Baptist Medical Center – Nassau and St. Vincent's Medical Center, offer the most advanced medical equipment and technology.

First Coast Oncology's practice is dedicated to advancing the understanding, treatment, and prevention of cancer through research, advocacy, and community service.  For more information, visit www.firstcoastoncology.com

SOURCE Naviscan, Inc.

RELATED LINKS
http://www.naviscan.com
http://www.firstcoastoncology.com

'/>"/>

SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Australien, 24. Februar 2017 ITL ... Unternehmen des Gesundheitsbereiches, ist erfreut, für das zum ... dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. ... Aktualisierung zum Wachstum" finden Sie hier . ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... 2017  Directors from Pharma To Market Pty Ltd and Ador ... resulting in the founding of Pharma To Market Pte Ltd, based ... are pleased to announce their expansion into Asia ... . The company are delighted to appoint Joelle Chia ... Singapore based entity. Joelle brings with her an ...
(Date:2/24/2017)... 2017 Non-alcoholic steatohepataitis (NASH) Pipeline ... drugs being developed for the treatment of ... that are in various phases of development ... on novel pharmacologic drugs & regenerative medicines ... recombinant proteins and RNA-based therapeutics, but excludes ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing ... B2B Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales leads based ... of IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling the sales ...
(Date:2/26/2017)... ... 2017 , ... ODH, Inc.™ announced today it will exhibit and speak ... City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will ... Medicaid population health management. , ODH will also have an exhibit booth where attendees ...
(Date:2/26/2017)... ... 2017 , ... Occupational pesticide exposure is linked to an ... according to a study released today at the 1st Pan American Parkinson’s and ... pesticides and incidence of sporadic PD through occupational exposure. This latest study, led ...
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, expert ... Core benefits and advantages built into the home office sit stand solution are ... feel. Ability to gain the benefits embedded in the TaskMate Go are available ...
(Date:2/24/2017)... ... ... two months after the official release of The Private Collection – Edition 2017 at ... a second print-run of its lavish luxury travel coffee table book. , An ... at more than six kilos, retails at EUR 1,000 per copy and is packed ...
Breaking Medicine News(10 mins):